United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, ...

Mirati Therapeutics Inc., an oncology company that focuses on the development of cancer therapeutics, and its corporate directors were slapped with a securities lawsuit on Nov. 14 in Delaware ...

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its Q3 2023 financial results, highlighting a net KRAZATI product revenue of $16.4 million. The company's cash, cash equivalents, and short-term ...

SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will ...

SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced the pricing of an underwritten public offering of ...

Mirati Therapeutics, Inc.'s stock currently trades at just over fifty bucks a share and sports an approximate market capitalization of $3 billion. Company Website.

Shares of Mirati Therapeutics Inc. jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a ...

Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 4.90% to $41.70 after Citigroup downgraded the stock from Buy to Neutral.

The analysts covering Mirati Therapeutics, Inc. (NASDAQ:MRTX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.